Interventional × Neuroendocrine Tumors × Lymphoid × Clear all
NCT02568267 2026-03-06

STARTRK-2

Hoffmann-La Roche

Phase 2 Active not recruiting
534 enrolled 2 FDA
NCT01638533 2025-02-07

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

National Cancer Institute (NCI)

Phase 1 Completed
37 enrolled
NCT04644315 2023-08-07

ALpha-T

Hoffmann-La Roche

Phase 2 Terminated
1 enrolled 5 charts